Drug Profile
Research programme: cytomegalovirus vector based immunotherapeutics - UbiVac
Alternative Names: CMV replication deficient vaccine - UbiVac; sdCMV 001; sdCMV 002Latest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator UbiVac
- Developer Oregon Health & Science University; UbiVac
- Class Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Human papillomavirus infections; Malignant melanoma
Most Recent Events
- 24 Aug 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 24 Aug 2023 Discontinued - Preclinical for Human papillomavirus infections in USA (Parenteral)
- 24 Aug 2023 Discontinued - Preclinical for Malignant melanoma in USA (Parenteral)